BCWORLD PHARM. Co. Ltd
BCWORLD PHARM. Co., Ltd. operates as a pharmaceutical company in South Korea. The company provides products in various therapeutic areas comprising musculoskeletal system, digestive system, circulatory machine, central nervous system, adrenocorticosteroids, narcotic analgesics, erectile dysfunction treatment, wellbeing injection, diuretic, antitussive expectorant, vaginitis treatment, anti-tuberc… Read more
BCWORLD PHARM. Co. Ltd (200780) - Net Assets
Latest net assets as of September 2025: ₩72.50 Billion KRW
Based on the latest financial reports, BCWORLD PHARM. Co. Ltd (200780) has net assets worth ₩72.50 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩173.79 Billion) and total liabilities (₩101.30 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩72.50 Billion |
| % of Total Assets | 41.71% |
| Annual Growth Rate | 1.44% |
| 5-Year Change | -24.61% |
| 10-Year Change | N/A |
| Growth Volatility | 9.47 |
BCWORLD PHARM. Co. Ltd - Net Assets Trend (2015–2024)
This chart illustrates how BCWORLD PHARM. Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BCWORLD PHARM. Co. Ltd (2015–2024)
The table below shows the annual net assets of BCWORLD PHARM. Co. Ltd from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩76.67 Billion | -6.09% |
| 2023-12-31 | ₩81.64 Billion | +2.63% |
| 2022-12-31 | ₩79.55 Billion | -2.34% |
| 2021-12-31 | ₩81.46 Billion | -19.90% |
| 2020-12-31 | ₩101.69 Billion | +4.58% |
| 2019-12-31 | ₩97.24 Billion | +7.94% |
| 2018-12-31 | ₩90.09 Billion | +10.91% |
| 2017-12-31 | ₩81.23 Billion | +9.95% |
| 2016-12-31 | ₩73.88 Billion | +9.61% |
| 2015-12-31 | ₩67.40 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to BCWORLD PHARM. Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 23.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩41.52 Billion | 54.16% |
| Common Stock | ₩1.78 Billion | 2.32% |
| Other Components | ₩33.37 Billion | 43.52% |
| Total Equity | ₩76.67 Billion | 100.00% |
BCWORLD PHARM. Co. Ltd Competitors by Market Cap
The table below lists competitors of BCWORLD PHARM. Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Prime Oil Chemical Service Corp
TW:2904
|
$19.55 Million |
|
DIAGNOS Inc
OTCQB:DGNOF
|
$19.55 Million |
|
Popular Vehicles and Services Limited
NSE:PVSL
|
$19.55 Million |
|
Samil Enterprise Co. Ltd
KQ:002290
|
$19.56 Million |
|
BACTIGUARD HLDG B
F:5JE
|
$19.54 Million |
|
LanzaTech Global Inc.
NASDAQ:LNZA
|
$19.54 Million |
|
Lion Chemtech Co. Ltd
KQ:171120
|
$19.53 Million |
|
Big Tree Cloud Holdings Limited Ordinary Shares
NASDAQ:DSY
|
$19.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BCWORLD PHARM. Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 81,642,992,680 to 76,667,758,590, a change of -4,975,234,090 (-6.1%).
- Net loss of 4,432,502,600 reduced equity.
- Dividend payments of 542,731,500 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-4.43 Billion | -5.78% |
| Dividends Paid | ₩542.73 Million | -0.71% |
| Other Changes | ₩10.00 | +0.0% |
| Total Change | ₩- | -6.09% |
Book Value vs Market Value Analysis
This analysis compares BCWORLD PHARM. Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.60x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩9607.15 | ₩4950.00 | x |
| 2017-12-31 | ₩9604.31 | ₩4950.00 | x |
| 2018-12-31 | ₩10653.52 | ₩4950.00 | x |
| 2019-12-31 | ₩11546.65 | ₩4950.00 | x |
| 2020-12-31 | ₩11909.98 | ₩4950.00 | x |
| 2021-12-31 | ₩9539.98 | ₩4950.00 | x |
| 2022-12-31 | ₩9427.18 | ₩4950.00 | x |
| 2023-12-31 | ₩8795.44 | ₩4950.00 | x |
| 2024-12-31 | ₩8259.45 | ₩4950.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BCWORLD PHARM. Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.92%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 2.30x
- Recent ROE (-5.78%) is below the historical average (4.41%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 9.39% | 15.28% | 0.52x | 1.18x | ₩-413.65 Million |
| 2016 | 8.76% | 14.18% | 0.47x | 1.31x | ₩-912.82 Million |
| 2017 | 9.95% | 16.10% | 0.42x | 1.46x | ₩-40.15 Million |
| 2018 | 9.63% | 15.74% | 0.34x | 1.80x | ₩-333.75 Million |
| 2019 | 6.23% | 11.71% | 0.30x | 1.78x | ₩-3.67 Billion |
| 2020 | 4.58% | 8.19% | 0.30x | 1.90x | ₩-5.51 Billion |
| 2021 | -2.26% | -2.97% | 0.35x | 2.20x | ₩-9.99 Billion |
| 2022 | 0.35% | 0.39% | 0.40x | 2.30x | ₩-7.67 Billion |
| 2023 | 3.23% | 3.51% | 0.41x | 2.26x | ₩-5.53 Billion |
| 2024 | -5.78% | -5.92% | 0.42x | 2.30x | ₩-12.10 Billion |
Industry Comparison
This section compares BCWORLD PHARM. Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $132,542,781,663
- Average return on equity (ROE) among peers: 3.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BCWORLD PHARM. Co. Ltd (200780) | ₩72.50 Billion | 9.39% | 1.40x | $19.54 Million |
| PharmGen Science Inc (004720) | $249.43 Billion | 1.12% | 0.46x | $34.69 Million |
| Korean Drug Co. Ltd (014570) | $65.05 Billion | 5.99% | 0.17x | $14.60 Million |
| Daishin Balance No.6 Special Purpose Acquisition Co. Ltd (307750) | $83.15 Billion | 4.86% | 0.29x | $65.86 Million |